J.C. Lopez-Talavera

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Viral Persistence, Viral Hepatitis, Immunodeficiencies +10

10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2012 · 24 citations

Viral Persistence, Viral Diagnostics, Viral Hepatitis +7

Prevalence of circulating antibodies against the hepatitis C virus among different risk groups in Spain

J.C. Lopez-Talavera, Esteban Ji, L Viladomiu et al. · Journal of Hepatology · 1989 · 15 citations

Vaccination, Hepatology, Hepatitis C +6

Entecavir results in higher HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naive adults: 24 wk results (EARLY study)

Nicole Yong Ting Leung, CY Peng, Jose D. Sollano et al. · 2006 · 15 citations

Viral Hepatitis, Wk Results, Immunology +9

[49] ENTECAVIR (ETV) RESULTS IN HIGHER HBV-DNA REDUCTION VS ADEFOVIR (ADV) IN CHRONICALLY INFECTED HBeAg(+) ANTIVIRAL-NAIVE ADULTS: 48 WK RESULTS (E.A.R.L. STUDY)

Nancy Leung, Cheng‐Yuan Peng, Jose D. Sollano et al. · Journal of Hepatology · 2007 · 10 citations · Full text

Wk Results, Immunology, Antiviral Therapy +7